Testosterone Therapy and Cardiovascular Risk: Advances and Controversies  Abraham Morgentaler, MD, Martin M. Miner, MD, Monica Caliber, MSc, Andre T. Guay, MD, Mohit Khera, MD, Abdulmaged M. Traish, PhD  Mayo Clinic Proceedings  Volume 90, Issue 2, Pages 224-251 (February 2015) DOI: 10.1016/j.mayocp.2014.10.011 Copyright © 2015 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure Actual percentage of individuals who experienced an adverse cardiovascular event in the testosterone (T)-treated and untreated groups in the study by Vigen et al.1 The authors reported a higher rate of adverse events in the T-treated group using inverse stabilized propensity weighting in which an event was counted as more than 1 event in the T-treated group and less than 1 event in the untreated group. MI = myocardial infarction. From J Sex Med,77 with permission. ©2014 International Society for Sexual Medicine. Mayo Clinic Proceedings 2015 90, 224-251DOI: (10.1016/j.mayocp.2014.10.011) Copyright © 2015 Mayo Foundation for Medical Education and Research Terms and Conditions